J101-0251 Screening compound: 3-(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}-3-oxopropyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione

J101-0251 Screening compound: 3-(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}-3-oxopropyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione
J101-0251 Screening compound: 3-(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}-3-oxopropyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione alternative view

Chemical Structure Depiction of ChemDiv screening compound J101-0251
3-(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}-3-oxopropyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

J101-0251

Molecular Formula

C23H25ClN4O3 (C23 H25 ClN4 O3)

Compound Name

3-(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}-3-oxopropyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione

IUPAC name

(3R)-3-(3-{4-[(2-chlorophenyl)methyl]piperazin-1-yl}-3-oxopropyl)-2345-tetrahydro-1H-14-benzodiazepine-25-dione

SMILES

O=C(CC[C@H](C(Nc1c2cccc1)=O)NC2=O)N1CCN(Cc(cccc2)c2Cl)CC1

InChI

InChI=1S/C23H25ClN4O3/c24-18-7-3-1-5-16(18)15-27-11-13-28(14-12-27)21(29)10-9-20-23(31)25-19-8-4-2-6-17(19)22(30)26-20/h1-8,20H,9-15H2,(H,25,31)(H,26,30)/t20-/m1/s1

InChI Key

YDUWVZUPNSWQIX-HXUWFJFHSA-N

MDL Number (MFCD)

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

440.93

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

6.00

Number of Nitrogen and Oxygen Atoms

7

Partition Coefficient, logP

2.515

Distribution Coefficient, logD

2.495

Water Solubility, LogSw

-3.44

Polar Surface Area

70.884

Acid Dissociation Constant (pKa)

9.01

Base Dissociation Constant (pKb)

5.74

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

34.80

J101-0251 in Drug Discovery

Included in Screening Libraries

Antiviral Library (67538 compounds)

Bcl2-PPI Inhibitors Library (12246 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

Neurotransmitter Transporter Inhibitors Library (11024 compounds)

PPI Inhibitors Tripeptide Mimetics (23972 compounds)

Protein-Protein Interaction Library (218420 compounds)

Beyond the Flatland Library sp3 enriched (92988 compounds)

New Agro Library (44492 compounds)

Peptidomimetic Library (37031 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Antiviral
  • Infections
  • Immune system
  • Cancer
  • Hemic and lymphatic
  • Nervous system
Mechanism of action:
  • PPI modulators
  • PPI modulators
  • PPI modulators
  • PPI modulators
Targets:
  • GPCR
  • Ion Channels
Structure:
  • Mimetics
  • Cyclic compounds
  • Mimetics
Agro:
  • Agro

References: we are preparing a list of scientific research reports with J101-0251 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound J101-0251?
Check Price and Availability of J101-0251, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of J101-0251 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for J101-0251
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for J101-0251
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of J101-0251 available by request